Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

Video

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab (JNJ-61186372) plus lazertinib (YH25448) in EGFR-mutant non–small cell lung cancer (NSCLC).

The rationale for combining amivantamab with lazertinib in advanced EGFR-mutated NSCLC involves several factors, says Spira. With regard to the relapsed/refractory population, many patients will have 1 of 2 mutations when they relapse: a C797S or a c-Met mutation or amplification. That is the main area of resistance for most patients previously treated with an EGFR inhibitor such as osimertinib (Tagrisso).

Amivantamab is a bispecific antibody; therefore, it targets c-Met in an attempt to overcome c-Met resistance, as well as EGFR in a different pathway. As a monoclonal antibody, it binds to the outside of the cell as opposed to a small molecule inhibitor that targets the inside of the cell. Lazertinib is very similar to osimertinib. By adding a second drug, mechanisms of resistance can potentially be overcome; there is a very strong scientific rationale for the study, concludes Spira.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD